BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26663886)

  • 1. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.
    Pericleous M; Caplin ME; Tsochatzis E; Yu D; Morgan-Rowe L; Toumpanakis C
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):61-9. PubMed ID: 26663886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
    Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
    Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
    Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
    Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis.
    Tai E; Kennedy S; Farrell A; Jaberi A; Kachura J; Beecroft R
    Curr Oncol; 2020 Dec; 27(6):e537-e546. PubMed ID: 33380868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
    Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
    HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
    Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
    Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
    Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA
    Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation.
    Kluger MD; Halazun KJ; Barroso RT; Fox AN; Olsen SK; Madoff DC; Siegel AB; Weintraub JL; Sussman J; Brown RS; Cherqui D; Emond JC
    Liver Transpl; 2014 May; 20(5):536-43. PubMed ID: 24493271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).
    Comito T; Loi M; Franzese C; Clerici E; Franceschini D; Badalamenti M; Teriaca MA; Rimassa L; Pedicini V; Poretti D; Solbiati LA; Torzilli G; Ceriani R; Lleo A; Aghemo A; Santoro A; Scorsetti M
    Curr Oncol; 2022 Nov; 29(11):8802-8813. PubMed ID: 36421345
    [No Abstract]   [Full Text] [Related]  

  • 13. Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?
    Kitano M; Davidson GW; Shirley LA; Schmidt CR; Guy GE; Khabiri H; Dowell JD; Shah MH; Bloomston M
    Ann Surg Oncol; 2016 Nov; 23(12):4008-4015. PubMed ID: 27393568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
    Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
    J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma.
    Tu J; Jia Z; Ying X; Zhang D; Li S; Tian F; Jiang G
    Medicine (Baltimore); 2016 Dec; 95(49):e5606. PubMed ID: 27930585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.
    Xie ZB; Ma L; Wang XB; Bai T; Ye JZ; Zhong JH; Li LQ
    Tumour Biol; 2014 Sep; 35(9):8451-9. PubMed ID: 25038916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma.
    Morse MA; Hanks BA; Suhocki P; Doan PL; Liu EA; Frost P; Bernard SA; Tsai A; Moore DT; O'Neil BH
    Clin Colorectal Cancer; 2012 Sep; 11(3):185-90. PubMed ID: 22280845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.
    Thornton LM; Cabrera R; Kapp M; Lazarowicz M; Vogel JD; Toskich BB
    Curr Probl Diagn Radiol; 2017; 46(6):402-409. PubMed ID: 28392205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.